ReviewBiological trace element research2026
Biogenic Zinc Oxide Nanoparticles for Skin Disorders: Mechanistic Insights, Translational Challenges, and Future Prospects.
Review in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising global burden of skin disorders necessitates the development of safe, effective, and sustainable therapeutic strategies. In this review, biogenic zinc oxide nanoparticles have emerged as a next-generation platform in dermatological nanomedicine, owing to their intrinsic antimicrobial, anti-inflammatory, photoprotective, and antioxidant properties. This review highlights recent advancements in biogenic ZnONPs synthesised via plant-mediated approaches, with comparative insights into their physicochemical characteristics, safety and biological activities. Mechanistically, biogenic ZnONPs operate through multimodal pathways, including microbial membrane disruption, modulation of inflammatory signalling, modulation of reactive oxygen species, promotion of reepithelization, and protection against UV-induced oxidative damage. Also, integrate multi-omics approaches to further advance understanding of nanoparticle-cell interactions at the cellular level. However, challenges such as a lack of standardised synthesis protocol, ion-mediated cytotoxicity, oxidative stress, and limited clinical validation remain significant barriers. Overall, biogenic ZnONPs represent a sustainable and versatile platform for transdermal therapy, but their clinical translation requires standerized synthesis, comprehensive safety evaluation, and well-designed preclinical and clinical studies.
Indexed as
Identifiers
42371386What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.